منابع مشابه
Anti – PD - 1 / PD - L 1 therapy of human cancer : past , present , and future
The PD pathway The cDNA of programmed cell death 1 (PD-1) was isolated in 1992 from a murine T cell hybridoma and a hematopoietic progenitor cell line undergoing apoptosis (1). Genetic ablation studies showed that deficiencies in PD-1 resulted in different autoimmune phenotypes in various mouse strains (2, 3). PD-1–deficient allogeneic T cells with transgenic T cell receptors exhibited augmente...
متن کاملDiffuse granulomatous panniculitis associated with anti PD-1 antibody therapy
PET/CT: positron emission tomography/ computed tomography INTRODUCTION Melanoma is one of the deadliest type of skin cancer, with a dismal 5-year survival rate for patients with metastatic melanoma. However, in the last decade, the development of novel immune therapy and targeted therapy has significantly improved overall survival in patients with advanced melanoma, and these therapies have rep...
متن کاملCytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.
PURPOSE Immunotherapy has experienced impressive progress in cancer treatment. Antibodies against PD-1 improved survival in different types of cancer including melanoma. They are generally well tolerated. However, skin toxicities including pruritus, rashes, and vitiligo are reported. Although frequent, they have not been characterized further yet. In this analysis, we aimed to systematically as...
متن کاملTranscriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Purpose: To explore factors associated with response and resistance to anti-PD-1 therapy, we analyzed multiple disease sites at autopsy in a patient with widely metastatic melanoma who had a heterogeneous response.Materials and Methods: Twenty-six melanoma specimens (four premortem, 22 postmortem) were subjected to whole exome sequencing. Candidate immunologic markers and gene expression were a...
متن کاملMetastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
BACKGROUND Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e.g., BRAF as in cutaneous melanoma. As a result, there...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2017
ISSN: 1759-4774,1759-4782
DOI: 10.1038/nrclinonc.2017.79